Age-related macular degeneration
New Zealand National Health Committee (NHC)
Record ID 32016000569
English
Authors' objectives:
Age-related macular degeneration (AMD) is the leading cause of blindness in New Zealand in those aged over 50, accounting for half of all cases. A referral for assessment of the vascular endothelial growth factor inhibitor (anti-VEGF) bevacizumab (Avastin) for the treatment of AMD was put forward as part of the 2013/14 referral round. This resulted in a Tier 2 assessment of AMD to confirm the most appropriate assessments within the context of the various interventions available for AMD and the wider model of care.
Authors' recommendations:
The NHC sought sector feedback on this document in the period from 12 March to 13 April 2015 and considered this at their May 2015 meeting. Following this feedback, the Tier 2 assessment was amended to correct minor inaccuracies and omissions.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://nhc.health.govt.nz/committee-publications/age-related-macular-degeneration
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
New Zealand
MeSH Terms
- Bevacizumab
- Angiogenesis Inhibitors
- Blindness
- Wet Macular Degeneration
- Vascular Endothelial Growth Factor A
Contact
Organisation Name:
New Zealand National Health Committee
Contact Address:
National Health Committee, PO Box 5013, 6145 Wellington New ZealandTel: +64 4 496 2120
Contact Name:
nhc_info@nhc.govt.nz
Contact Email:
nhc_info@nhc.govt.nz
Copyright:
New Zealand National Health Committee (NHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.